A Study of LY3361237 in Participants With Systemic Lupus Erythematosus

I9S-MC-BTAB -

The main purpose of this study is to learn more about the safety of LY3361237 and any side effects that might be associated with it when given to participants with systemic lupus erythematosis (SLE). LY3361237 will be administered by injections just under the skin.

Trial Summary

Age Range
18 - 70 years
Conditions the trial is for
Systemic Lupus Erythematosus
What the trial is testing?
LY3361237
Could I receive a Placebo?
Yes
Enrollment Goal
28
Trial Dates
May 21, 2019 - Feb 15, 2021
How long will I be in the trial?
The study will last up to 26.5 weeks and may include up to 17 visits to the study center.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have been diagnosed with SLE at least 6 months before enrollment

  • Participants taking an oral steroid called prednisone (or equivalent) must be taking no more than 20 milligrams for at least 2 months and must be on a stable dose

  • Participants taking other common medications for SLE must be on the medication for at least 3 months with a stable dose for at least 2 months

Participants Must Not:

  • Participants must not have or have had any other diseases that cause inflammation of the joints or skin

  • Participants must not have an active infection.

  • Participants must not have serious liver or kidney dysfunction

  • Participants must not have taken medications to destroy cancer cells within the last 3 months

  • Participants must not have had a blood transfusion within the last year

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.